Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LARS1 | Q9P2J5 | 1/20 | 0.43 |
| ▸ | PLG | P00747 | 1/20 | 0.39 |
| ▸ | SCD | O00767 | 2/20 | 0.38 |
| ▸ | SCD5 | Q86SK9 | 2/20 | 0.38 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | F2 | P00734 | 2/20 | 0.38 |
| ▸ | PARG | Q86W56 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | TRHDE | Q9UKU6 | 1/20 | 0.37 |
| ▸ | HTR7 | P34969 | 1/20 | 0.36 |
| ▸ | F10 | P00742 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3097141 | 0.92 | BCHE (0.39) | LARS1PLGSCDSCD5NR1I2 | |
| SCHEMBL3090411 | 0.91 | LARS1 (0.40) | LARS1PLGLMNAF2ALDH1A1 | |
| SCHEMBL3091744 | 0.91 | LARS1 (0.41) | LARS1PLGLMNAF2ALDH1A1 | |
| SCHEMBL3096206 | 0.91 | LARS1 (0.41) | LARS1PLGSCDSCD5NR1I2 | |
| Trifluoroacetic Acid SCHEMBL3091304 | 0.90 | LARS1 (0.37) | LARS1PLGNR1I2F2KMT2A | |
| SCHEMBL3103667 | 0.89 | LARS1 (0.40) | LARS1PLGSCDSCD5F2 | |
| SCHEMBL3470358 | 0.89 | LARS1 (0.46) | LARS1SCDSCD5NR1I2LMNA | |
| SCHEMBL3093166 | 0.87 | LARS1 (0.41) | LARS1PLGSCDSCD5LMNA | |
| SCHEMBL3103267 | 0.87 | LARS1 (0.39) | LARS1PLGLMNAF2ALDH1A1 | |
| SCHEMBL3103273 | 0.87 | LARS1 (0.39) | LARS1PLGLMNAF2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8461209-B2 | Malonic acid sulfonamide derivative and pharmaceutical use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-06-11 | — | — | US | disclosed |
| US-20100228026-A1 | NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-09-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100228026-A1 | NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | REN, AGTR2, AGTR1 | LARS1 1976/4885PLG 2448/4885SCD 504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.